Findlay Park Partners LLP Sells 27,500 Shares of STERIS plc $STE

Findlay Park Partners LLP trimmed its holdings in shares of STERIS plc (NYSE:STE) by 3.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 760,652 shares of the medical equipment provider’s stock after selling 27,500 shares during the period. STERIS makes up about 1.9% of Findlay Park Partners LLP’s investment portfolio, making the stock its 20th largest holding. Findlay Park Partners LLP owned 0.77% of STERIS worth $182,724,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of STE. Spurstone Advisory Services LLC purchased a new stake in shares of STERIS during the second quarter valued at $29,000. Geneos Wealth Management Inc. lifted its stake in STERIS by 416.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 104 shares during the period. Zions Bancorporation National Association UT purchased a new stake in shares of STERIS during the 1st quarter valued at about $37,000. Costello Asset Management INC bought a new stake in shares of STERIS in the first quarter worth approximately $45,000. Finally, Generali Investments Management Co LLC purchased a new position in shares of STERIS during the second quarter valued at approximately $56,000. Hedge funds and other institutional investors own 94.69% of the company’s stock.

STERIS Trading Down 0.3%

NYSE:STE opened at $266.98 on Thursday. STERIS plc has a one year low of $200.98 and a one year high of $268.60. The business has a fifty day moving average price of $247.97 and a 200-day moving average price of $242.39. The firm has a market capitalization of $26.20 billion, a price-to-earnings ratio of 40.89 and a beta of 1.02. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.22 and a quick ratio of 1.53.

STERIS (NYSE:STE) last released its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.38 by $0.09. STERIS had a return on equity of 14.17% and a net margin of 11.61%.The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. During the same quarter in the previous year, the company posted $2.14 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. Sell-side analysts forecast that STERIS plc will post 9.08 EPS for the current year.

STERIS Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 18th. Shareholders of record on Tuesday, November 18th will be paid a dividend of $0.63 per share. The ex-dividend date is Tuesday, November 18th. This represents a $2.52 dividend on an annualized basis and a yield of 0.9%. STERIS’s dividend payout ratio (DPR) is presently 36.21%.

Analyst Upgrades and Downgrades

STE has been the subject of a number of research reports. Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a research note on Tuesday, October 14th. Wall Street Zen upgraded STERIS from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 14th. Finally, Morgan Stanley raised their target price on STERIS from $276.00 to $295.00 and gave the stock an “overweight” rating in a research report on Friday, August 8th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $273.50.

Insider Activity

In related news, VP John Adam Zangerle sold 15,000 shares of STERIS stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $265.14, for a total transaction of $3,977,100.00. Following the transaction, the vice president owned 33,669 shares in the company, valued at approximately $8,926,998.66. The trade was a 30.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Renato Tamaro sold 5,036 shares of the company’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $257.55, for a total transaction of $1,297,021.80. Following the completion of the transaction, the vice president directly owned 5,695 shares of the company’s stock, valued at $1,466,747.25. This represents a 46.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 25,203 shares of company stock worth $6,624,667 over the last ninety days. Company insiders own 1.07% of the company’s stock.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.